<?xml version="1.0" encoding="UTF-8"?>
<p>In 2015, ~71 million people worldwide suffered from chronic hepatitis C virus (HCV) infection [
 <xref rid="CIT0001" ref-type="bibr">1</xref>]. Currently the World Health Organization (WHO) is calling for a reduction of new infections by 90% and mortality by 65% by 2030, with the ultimate aim of HCV elimination [
 <xref rid="CIT0001" ref-type="bibr">1</xref>]. This ambitious goal is driven by the tremendous improvements in HCV therapy that have been achieved due to the development of direct-acting antivirals (DAAs).
</p>
